PhotoMedex Announces Annual Stockholders' Meeting

Information on the Stockholders' Meeting, including routine proposals and proposals related to the transaction with Photo Therapeutics, that will be considered at the Stockholders' Meeting and the manner in which stockholders may vote, is set forth in PhotoMedex, Inc.'s Definitive Proxy Statement filed with the Securities and Exchange Commission on December 18, 2008 and mailed to PhotoMedex's stockholders of record as of December 1, 2008.

About PhotoMedex

PhotoMedex is engaged in the development of proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA 510(k) clearances to market the XTRAC(R) laser system for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. In addition, the Company provides contract medical procedures to hospitals, surgi-centers and doctors' offices, offering a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics, and other surgical specialties. The Company is a leader in the development, manufacturing and marketing of medical laser products and services. In addition, as a result of the merger with ProCyte, PhotoMedex now develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).

Stockholders' Meeting Information

This press release includes forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on managements' current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

In connection with the Stockholders' Meeting, PhotoMedex filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on December 18, 2008 and may file other relevant documents. PhotoMedex's stockholders are urged to read the proxy statement (and any other relevant documents filed with the SEC when they become available), because they will contain important information about the proposals to be considered at the Stockholders' Meeting. PhotoMedex mailed the definitive proxy statement to its stockholders, who may also obtain free copies of the proxy statement, as well as PhotoMedex's other filings, without charge, at the SEC's Web site (www.sec.gov) when they become available. Copies of the filings may also be obtained without charge from PhotoMedex by directing a request to: 147 Keystone Drive, Montgomeryville, Pennsylvania, 18936, Attention: Corporate Counsel.

PhotoMedex's directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from stockholders in respect of the Stockholders' Meeting. Information regarding PhotoMedex's directors and executive officers is available in the Company's 2007 Annual Report on Form 10-K, filed with the SEC on March 17, 2008, as amended by the Company's annual report on Form 10-K/A as filed with the SEC on May 8, 2008. Additional information regarding the interests of such potential participants has been included in the proxy statement and will be the other relevant documents filed with the SEC when they become available.

SOURCE: PhotoMedex, Inc.

Company Contact: PhotoMedex, Inc. Dennis McGrath, CFO 215-619-3287 info@photomedex.com or Investor Contacts: Lippert/Heilshorn & Associates, Inc. Kim Sutton Golodetz 212-838-3777 Kgolodetz@lhai.com Bruce Voss 310-691-7100 Bvoss@lhai.com